Bio-Rad Laboratories (BIO)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$386.11-0.46%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · BIO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 14.7% |
| Our one-year growth estimate | diamond | 2.0% |
Growth built into the price is above our model estimate.
The price assumes 12.6 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
BIO — workforce reduction
Dated 2026-08-04
above constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning the Company’s expectations or estimates relating to the restructuring plan, including the anticipated workforce reduction, timing of completion of the restructuring plan, the ability of the Company to manage local employee consultative processes, and timing and amounts of the charges to be recorded and cash expenditures…
Why it matters: If Stilla Technologies joins well, it may help Bio-Rad's products. This could make Bio-Rad stronger in the market.
Supportive ifLook for positive market feedback or sales growth in the ddPCR product line after integration.
Worry ifWatch for negative market feedback or flat sales in the ddPCR product line after integration.
Why it matters: Funding levels directly affect Bio-Rad's Life Science segment. A significant drop could lead to lower sales.
Worry ifReports show a big drop in academic research funding.
Less concerning ifFunding levels are stable or rising. This supports Bio-Rad's Life Science segment.
Why it matters: Ongoing losses may worry people about Bio-Rad's money and how it runs.
Worry ifQ2 earnings report shows losses greater than the previous quarter.
Less concerning ifQ2 earnings report shows profits or smaller losses than last quarter.
Why it matters: Changes to revenue guidance show how management reacts to market conditions. It affects trust.
Worry ifManagement raises the 2026 revenue growth forecast to more than -3.0%.
Less concerning ifManagement lowers the full-year 2026 revenue growth guidance from -3.0%.
Why it matters: News about job changes shows how well the company controls costs and market problems.
Watch forManagement gives a clear timeline and expected gains from the workforce cuts.
Also watch forThere are no updates or bad news about the workforce plan.
Why it matters: Success in integrating Stilla Technologies could boost Bio-Rad's growth in digital PCR. This is key for future revenue.
Supportive ifGood news on Stilla Technologies' product growth and sales.
Worry ifBad news or delays in Stilla Technologies' market results.
Why it matters: A drop in revenue growth would signal a potential slowdown in the sector. This could impact Bio-Rad's performance and outlook.
Worry ifRevenue growth falls below the median level for the sector.
Less concerning ifRevenue growth remains above the median level for the sector.
Why it matters: This margin shows management is good at controlling costs. It helps long-term profits.
Supportive ifNon-GAAP operating margin reaches or exceeds 10% in Q3.
Worry ifNon-GAAP operating margin falls below 10% in Q3.
Why it matters: A drop below this level would confirm ongoing challenges in Bio-Rad's markets. It would show that revenue growth is not recovering as expected.
Worry ifQ2 2026 revenue shows a drop of -3.0% compared to last year.
Less concerning ifQ2 2026 revenue growth is better than -3.0%. This shows market conditions are improving.
Why it matters: Changes in funding can impact Bio-Rad's Life Science segment sales. This is key to understanding revenue trends.
Watch forMore funding for academic research boosts Life Science segment sales.
Also watch forLess funding for academic research causes more drops in Life Science segment sales.
Why it matters: A bigger drop would show more problems in the academic research market.
Worry ifLife Science segment sales decline worse than -5.1% year over year.
Less concerning ifLife Science segment sales decline less than -5.1% year over year.
Why it matters: Growth above this level shows strong demand and good product plans.
Supportive ifClinical Diagnostics segment revenue grew over 2.6% from last year.
Worry ifClinical Diagnostics segment revenue grew below 2.6% from last year.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$90 on $10,000 · ±0.9% | How much price usually moves either way. |
| Bad day | $312 loss on $10,000 · 3.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,886 loss on $10,000 · 28.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.